Progyny, Inc. (NASDAQ:PGNY) Director Sells $41,506.18 in Stock

Progyny, Inc. (NASDAQ:PGNY) Director Cheryl Scott sold 1,462 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $28.39, for a total value of $41,506.18. Following the completion of the sale, the director now owns 10,098 shares in the company, valued at $286,682.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Progyny Stock Down 0.8 %

NASDAQ PGNY traded down $0.23 on Monday, reaching $28.38. The company had a trading volume of 1,243,484 shares, compared to its average volume of 971,181. The stock has a market capitalization of $2.70 billion, a P/E ratio of 46.90, a P/E/G ratio of 1.85 and a beta of 1.46. The company’s fifty day moving average is $28.62 and its 200 day moving average is $34.19. Progyny, Inc. has a 52-week low of $23.90 and a 52-week high of $44.95.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.17 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The business had revenue of $278.08 million during the quarter, compared to analyst estimates of $289.41 million. Progyny had a return on equity of 11.61% and a net margin of 5.53%. Progyny’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.18 EPS. On average, research analysts expect that Progyny, Inc. will post 0.73 EPS for the current year.

Analysts Set New Price Targets

PGNY has been the topic of a number of research analyst reports. Barclays cut their price target on Progyny from $48.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, May 13th. Truist Financial cut their price target on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 17th. Cantor Fitzgerald restated an “overweight” rating and set a $48.00 price target on shares of Progyny in a report on Thursday, May 16th. BTIG Research cut their price target on Progyny from $50.00 to $41.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Finally, Canaccord Genuity Group cut their price target on Progyny from $46.00 to $37.00 and set a “buy” rating on the stock in a report on Friday, May 10th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.11.

Institutional Investors Weigh In On Progyny

Institutional investors and hedge funds have recently bought and sold shares of the stock. Parkside Financial Bank & Trust grew its stake in Progyny by 9.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock valued at $115,000 after purchasing an additional 264 shares during the period. Caprock Group LLC grew its stake in shares of Progyny by 5.3% during the 1st quarter. Caprock Group LLC now owns 6,288 shares of the company’s stock worth $240,000 after acquiring an additional 319 shares during the period. RiverPark Advisors LLC grew its stake in shares of Progyny by 54.0% during the 4th quarter. RiverPark Advisors LLC now owns 1,067 shares of the company’s stock worth $40,000 after acquiring an additional 374 shares during the period. M&G Investment Management Ltd. grew its stake in shares of Progyny by 1.2% during the 4th quarter. M&G Investment Management Ltd. now owns 32,980 shares of the company’s stock worth $1,220,000 after acquiring an additional 387 shares during the period. Finally, FourThought Financial Partners LLC grew its stake in shares of Progyny by 1.3% during the 4th quarter. FourThought Financial Partners LLC now owns 32,683 shares of the company’s stock worth $1,215,000 after acquiring an additional 423 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.